Global Biologics and Biosimilars Market Research Report 2022
Global Biologics and Biosimilars Market Overview:
Global Biologics and Biosimilars Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Biologics and Biosimilars involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Biologics and Biosimilars Market
The Biologics and Biosimilars Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Biologics and Biosimilars Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Biologics and Biosimilars Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Biologics and Biosimilars Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Biologics and Biosimilars market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Biologics and Biosimilars Market Segmentation
Global Biologics and Biosimilars Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Biologics and Biosimilars market has been segmented into:
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
By Application, Biologics and Biosimilars market has been segmented into:
Tumor
Diabetes
Cardiovascular
Hemophilia
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Biologics and Biosimilars market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Biologics and Biosimilars market.
Top Key Players Covered in Biologics and Biosimilars market are:
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Other Major Players
Objective to buy this Report:
1. Biologics and Biosimilars analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Biologics and Biosimilars market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Global Biologics and Biosimilars Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Biologics and Biosimilars involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Biologics and Biosimilars Market
The Biologics and Biosimilars Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Biologics and Biosimilars Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Biologics and Biosimilars Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Biologics and Biosimilars Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Biologics and Biosimilars market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Biologics and Biosimilars Market Segmentation
Global Biologics and Biosimilars Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Biologics and Biosimilars market has been segmented into:
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
By Application, Biologics and Biosimilars market has been segmented into:
Tumor
Diabetes
Cardiovascular
Hemophilia
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Biologics and Biosimilars market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Biologics and Biosimilars market.
Top Key Players Covered in Biologics and Biosimilars market are:
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Other Major Players
Objective to buy this Report:
1. Biologics and Biosimilars analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Biologics and Biosimilars market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
CHAPTER 1: INTRODUCTION
1.1 RESEARCH OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.3 RESEARCH PROCESS
1.4 SCOPE AND COVERAGE
1.4.1 MARKET DEFINITION
1.4.2 KEY QUESTIONS ANSWERED
1.5 MARKET SEGMENTATION
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 BY TYPE
3.2 BY APPLICATION
CHAPTER 4: MARKET LANDSCAPE
4.1 PORTER'S FIVE FORCES ANALYSIS
4.1.1 BARGAINING POWER OF SUPPLIER
4.1.2 THREAT OF NEW ENTRANTS
4.1.3 THREAT OF SUBSTITUTES
4.1.4 COMPETITIVE RIVALRY
4.1.5 BARGAINING POWER AMONG BUYERS
4.2 INDUSTRY VALUE CHAIN ANALYSIS
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.2 RESTRAINTS
4.3.3 OPPORTUNITIES
4.5.4 CHALLENGES
4.4 PESTLE ANALYSIS
4.5 TECHNOLOGICAL ROADMAP
4.6 REGULATORY LANDSCAPE
4.7 SWOT ANALYSIS
4.8 PRICE TREND ANALYSIS
4.9 PATENT ANALYSIS
4.10 ANALYSIS OF THE IMPACT OF COVID-19
4.10.1 IMPACT ON THE OVERALL MARKET
4.10.2 IMPACT ON THE SUPPLY CHAIN
4.10.3 IMPACT ON THE KEY MANUFACTURERS
4.10.4 IMPACT ON THE PRICING
CHAPTER 5: BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
5.1 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
5.2 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW
5.3 MONOCLONAL ANTIBODIES
5.3.1 INTRODUCTION AND MARKET OVERVIEW
5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.3.4 MONOCLONAL ANTIBODIES: GEOGRAPHIC SEGMENTATION
5.4 INTERFERON
5.4.1 INTRODUCTION AND MARKET OVERVIEW
5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.4.4 INTERFERON: GEOGRAPHIC SEGMENTATION
5.5 ERYTHROPOIETIN
5.5.1 INTRODUCTION AND MARKET OVERVIEW
5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.5.4 ERYTHROPOIETIN: GEOGRAPHIC SEGMENTATION
5.6 INSULIN
5.6.1 INTRODUCTION AND MARKET OVERVIEW
5.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.6.4 INSULIN: GEOGRAPHIC SEGMENTATION
5.7 VACCINES
5.7.1 INTRODUCTION AND MARKET OVERVIEW
5.7.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.7.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.7.4 VACCINES: GEOGRAPHIC SEGMENTATION
5.8 OTHERS
5.8.1 INTRODUCTION AND MARKET OVERVIEW
5.8.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.8.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.8.4 OTHERS: GEOGRAPHIC SEGMENTATION
5.9
5.9.1 INTRODUCTION AND MARKET OVERVIEW
5.9.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.9.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.9.4 : GEOGRAPHIC SEGMENTATION
CHAPTER 6: BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
6.1 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
6.2 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW
6.3 TUMOR
6.3.1 INTRODUCTION AND MARKET OVERVIEW
6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.3.4 TUMOR: GEOGRAPHIC SEGMENTATION
6.4 DIABETES
6.4.1 INTRODUCTION AND MARKET OVERVIEW
6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.4.4 DIABETES: GEOGRAPHIC SEGMENTATION
6.5 CARDIOVASCULAR
6.5.1 INTRODUCTION AND MARKET OVERVIEW
6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.5.4 CARDIOVASCULAR: GEOGRAPHIC SEGMENTATION
6.6 HEMOPHILIA
6.6.1 INTRODUCTION AND MARKET OVERVIEW
6.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.6.4 HEMOPHILIA : GEOGRAPHIC SEGMENTATION
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 COMPETITIVE LANDSCAPE
7.1.1 COMPETITIVE POSITIONING
7.1.2 BIOLOGICS AND BIOSIMILARS SALES AND MARKET SHARE BY PLAYERS
7.1.3 INDUSTRY BCG MATRIX
7.1.4 HEAT MAP ANALYSIS
7.1.5 BIOLOGICS AND BIOSIMILARS INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
7.1.6 TOP 5 BIOLOGICS AND BIOSIMILARS PLAYERS MARKET SHARE
7.1.7 MERGERS AND ACQUISITIONS
7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
7.2 ROCHE
7.2.1 COMPANY OVERVIEW
7.2.2 KEY EXECUTIVES
7.2.3 COMPANY SNAPSHOT
7.2.4 OPERATING BUSINESS SEGMENTS
7.2.5 PRODUCT PORTFOLIO
7.2.6 BUSINESS PERFORMANCE
7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
7.2.8 SWOT ANALYSIS
7.3 AMGEN
7.4 ABBVIE
7.5 SANOFI-AVENTIS
7.6 JOHNSON & JOHNSON
7.7 PFIZER
7.8 NOVO NORDISK
7.9 ELI LILLY
7.10 NOVARTIS
7.11 MERCK
7.12 3SBIO
7.13 CHANGCHUN HIGH TECH
7.14 CP GUOJIAN
7.15 BIOTECH
7.16 GELGEN
7.17 INNOVENT
7.18 DONG BAO
7.19 GANLEE
7.20 UNITED LABORATORIES
7.21 OTHER MAJOR PLAYERS
CHAPTER 8: GLOBAL BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 MARKET OVERVIEW
8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
8.2.1 MONOCLONAL ANTIBODIES
8.2.2 INTERFERON
8.2.3 ERYTHROPOIETIN
8.2.4 INSULIN
8.2.5 VACCINES
8.2.6 OTHERS
8.2.7
8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
8.3.1 TUMOR
8.3.2 DIABETES
8.3.3 CARDIOVASCULAR
8.3.4 HEMOPHILIA
CHAPTER 9: NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.2 IMPACT OF COVID-19
9.3 KEY PLAYERS
9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
9.4.1 MONOCLONAL ANTIBODIES
9.4.2 INTERFERON
9.4.3 ERYTHROPOIETIN
9.4.4 INSULIN
9.4.5 VACCINES
9.4.6 OTHERS
9.4.7
9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
9.5.1 TUMOR
9.5.2 DIABETES
9.5.3 CARDIOVASCULAR
9.5.4 HEMOPHILIA
9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
9.6.1 U.S.
9.6.2 CANADA
9.6.3 MEXICO
CHAPTER 10: EUROPE BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.2 IMPACT OF COVID-19
10.3 KEY PLAYERS
10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
10.4.1 MONOCLONAL ANTIBODIES
10.4.2 INTERFERON
10.4.3 ERYTHROPOIETIN
10.4.4 INSULIN
10.4.5 VACCINES
10.4.6 OTHERS
10.4.7
10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
10.5.1 TUMOR
10.5.2 DIABETES
10.5.3 CARDIOVASCULAR
10.5.4 HEMOPHILIA
10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
10.6.1 GERMANY
10.6.2 U.K.
10.6.3 FRANCE
10.6.4 ITALY
10.6.5 RUSSIA
10.6.6 SPAIN
10.6.7 REST OF EUROPE
CHAPTER 11: ASIA-PACIFIC BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.2 IMPACT OF COVID-19
11.3 KEY PLAYERS
11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
11.4.1 MONOCLONAL ANTIBODIES
11.4.2 INTERFERON
11.4.3 ERYTHROPOIETIN
11.4.4 INSULIN
11.4.5 VACCINES
11.4.6 OTHERS
11.4.7
11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
11.5.1 TUMOR
11.5.2 DIABETES
11.5.3 CARDIOVASCULAR
11.5.4 HEMOPHILIA
11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
11.6.1 CHINA
11.6.2 INDIA
11.6.3 JAPAN
11.6.4 SINGAPORE
11.6.5 AUSTRALIA
11.6.6 NEW ZEALAND
11.6.7 REST OF APAC
CHAPTER 12: MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.2 IMPACT OF COVID-19
12.3 KEY PLAYERS
12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
12.4.1 MONOCLONAL ANTIBODIES
12.4.2 INTERFERON
12.4.3 ERYTHROPOIETIN
12.4.4 INSULIN
12.4.5 VACCINES
12.4.6 OTHERS
12.4.7
12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
12.5.1 TUMOR
12.5.2 DIABETES
12.5.3 CARDIOVASCULAR
12.5.4 HEMOPHILIA
12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
12.6.1 TURKEY
12.6.2 SAUDI ARABIA
12.6.3 IRAN
12.6.4 UAE
12.6.5 AFRICA
12.6.6 REST OF MEA
CHAPTER 13: SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.2 IMPACT OF COVID-19
13.3 KEY PLAYERS
13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
13.4.1 MONOCLONAL ANTIBODIES
13.4.2 INTERFERON
13.4.3 ERYTHROPOIETIN
13.4.4 INSULIN
13.4.5 VACCINES
13.4.6 OTHERS
13.4.7
13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
13.5.1 TUMOR
13.5.2 DIABETES
13.5.3 CARDIOVASCULAR
13.5.4 HEMOPHILIA
13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
13.6.1 BRAZIL
13.6.2 ARGENTINA
13.6.3 REST OF SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
1.1 RESEARCH OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.3 RESEARCH PROCESS
1.4 SCOPE AND COVERAGE
1.4.1 MARKET DEFINITION
1.4.2 KEY QUESTIONS ANSWERED
1.5 MARKET SEGMENTATION
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 BY TYPE
3.2 BY APPLICATION
CHAPTER 4: MARKET LANDSCAPE
4.1 PORTER'S FIVE FORCES ANALYSIS
4.1.1 BARGAINING POWER OF SUPPLIER
4.1.2 THREAT OF NEW ENTRANTS
4.1.3 THREAT OF SUBSTITUTES
4.1.4 COMPETITIVE RIVALRY
4.1.5 BARGAINING POWER AMONG BUYERS
4.2 INDUSTRY VALUE CHAIN ANALYSIS
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.2 RESTRAINTS
4.3.3 OPPORTUNITIES
4.5.4 CHALLENGES
4.4 PESTLE ANALYSIS
4.5 TECHNOLOGICAL ROADMAP
4.6 REGULATORY LANDSCAPE
4.7 SWOT ANALYSIS
4.8 PRICE TREND ANALYSIS
4.9 PATENT ANALYSIS
4.10 ANALYSIS OF THE IMPACT OF COVID-19
4.10.1 IMPACT ON THE OVERALL MARKET
4.10.2 IMPACT ON THE SUPPLY CHAIN
4.10.3 IMPACT ON THE KEY MANUFACTURERS
4.10.4 IMPACT ON THE PRICING
CHAPTER 5: BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
5.1 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
5.2 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW
5.3 MONOCLONAL ANTIBODIES
5.3.1 INTRODUCTION AND MARKET OVERVIEW
5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.3.4 MONOCLONAL ANTIBODIES: GEOGRAPHIC SEGMENTATION
5.4 INTERFERON
5.4.1 INTRODUCTION AND MARKET OVERVIEW
5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.4.4 INTERFERON: GEOGRAPHIC SEGMENTATION
5.5 ERYTHROPOIETIN
5.5.1 INTRODUCTION AND MARKET OVERVIEW
5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.5.4 ERYTHROPOIETIN: GEOGRAPHIC SEGMENTATION
5.6 INSULIN
5.6.1 INTRODUCTION AND MARKET OVERVIEW
5.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.6.4 INSULIN: GEOGRAPHIC SEGMENTATION
5.7 VACCINES
5.7.1 INTRODUCTION AND MARKET OVERVIEW
5.7.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.7.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.7.4 VACCINES: GEOGRAPHIC SEGMENTATION
5.8 OTHERS
5.8.1 INTRODUCTION AND MARKET OVERVIEW
5.8.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.8.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.8.4 OTHERS: GEOGRAPHIC SEGMENTATION
5.9
5.9.1 INTRODUCTION AND MARKET OVERVIEW
5.9.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.9.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.9.4 : GEOGRAPHIC SEGMENTATION
CHAPTER 6: BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
6.1 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
6.2 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW
6.3 TUMOR
6.3.1 INTRODUCTION AND MARKET OVERVIEW
6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.3.4 TUMOR: GEOGRAPHIC SEGMENTATION
6.4 DIABETES
6.4.1 INTRODUCTION AND MARKET OVERVIEW
6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.4.4 DIABETES: GEOGRAPHIC SEGMENTATION
6.5 CARDIOVASCULAR
6.5.1 INTRODUCTION AND MARKET OVERVIEW
6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.5.4 CARDIOVASCULAR: GEOGRAPHIC SEGMENTATION
6.6 HEMOPHILIA
6.6.1 INTRODUCTION AND MARKET OVERVIEW
6.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.6.4 HEMOPHILIA : GEOGRAPHIC SEGMENTATION
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 COMPETITIVE LANDSCAPE
7.1.1 COMPETITIVE POSITIONING
7.1.2 BIOLOGICS AND BIOSIMILARS SALES AND MARKET SHARE BY PLAYERS
7.1.3 INDUSTRY BCG MATRIX
7.1.4 HEAT MAP ANALYSIS
7.1.5 BIOLOGICS AND BIOSIMILARS INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
7.1.6 TOP 5 BIOLOGICS AND BIOSIMILARS PLAYERS MARKET SHARE
7.1.7 MERGERS AND ACQUISITIONS
7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
7.2 ROCHE
7.2.1 COMPANY OVERVIEW
7.2.2 KEY EXECUTIVES
7.2.3 COMPANY SNAPSHOT
7.2.4 OPERATING BUSINESS SEGMENTS
7.2.5 PRODUCT PORTFOLIO
7.2.6 BUSINESS PERFORMANCE
7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
7.2.8 SWOT ANALYSIS
7.3 AMGEN
7.4 ABBVIE
7.5 SANOFI-AVENTIS
7.6 JOHNSON & JOHNSON
7.7 PFIZER
7.8 NOVO NORDISK
7.9 ELI LILLY
7.10 NOVARTIS
7.11 MERCK
7.12 3SBIO
7.13 CHANGCHUN HIGH TECH
7.14 CP GUOJIAN
7.15 BIOTECH
7.16 GELGEN
7.17 INNOVENT
7.18 DONG BAO
7.19 GANLEE
7.20 UNITED LABORATORIES
7.21 OTHER MAJOR PLAYERS
CHAPTER 8: GLOBAL BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 MARKET OVERVIEW
8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
8.2.1 MONOCLONAL ANTIBODIES
8.2.2 INTERFERON
8.2.3 ERYTHROPOIETIN
8.2.4 INSULIN
8.2.5 VACCINES
8.2.6 OTHERS
8.2.7
8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
8.3.1 TUMOR
8.3.2 DIABETES
8.3.3 CARDIOVASCULAR
8.3.4 HEMOPHILIA
CHAPTER 9: NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.2 IMPACT OF COVID-19
9.3 KEY PLAYERS
9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
9.4.1 MONOCLONAL ANTIBODIES
9.4.2 INTERFERON
9.4.3 ERYTHROPOIETIN
9.4.4 INSULIN
9.4.5 VACCINES
9.4.6 OTHERS
9.4.7
9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
9.5.1 TUMOR
9.5.2 DIABETES
9.5.3 CARDIOVASCULAR
9.5.4 HEMOPHILIA
9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
9.6.1 U.S.
9.6.2 CANADA
9.6.3 MEXICO
CHAPTER 10: EUROPE BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.2 IMPACT OF COVID-19
10.3 KEY PLAYERS
10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
10.4.1 MONOCLONAL ANTIBODIES
10.4.2 INTERFERON
10.4.3 ERYTHROPOIETIN
10.4.4 INSULIN
10.4.5 VACCINES
10.4.6 OTHERS
10.4.7
10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
10.5.1 TUMOR
10.5.2 DIABETES
10.5.3 CARDIOVASCULAR
10.5.4 HEMOPHILIA
10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
10.6.1 GERMANY
10.6.2 U.K.
10.6.3 FRANCE
10.6.4 ITALY
10.6.5 RUSSIA
10.6.6 SPAIN
10.6.7 REST OF EUROPE
CHAPTER 11: ASIA-PACIFIC BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.2 IMPACT OF COVID-19
11.3 KEY PLAYERS
11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
11.4.1 MONOCLONAL ANTIBODIES
11.4.2 INTERFERON
11.4.3 ERYTHROPOIETIN
11.4.4 INSULIN
11.4.5 VACCINES
11.4.6 OTHERS
11.4.7
11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
11.5.1 TUMOR
11.5.2 DIABETES
11.5.3 CARDIOVASCULAR
11.5.4 HEMOPHILIA
11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
11.6.1 CHINA
11.6.2 INDIA
11.6.3 JAPAN
11.6.4 SINGAPORE
11.6.5 AUSTRALIA
11.6.6 NEW ZEALAND
11.6.7 REST OF APAC
CHAPTER 12: MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.2 IMPACT OF COVID-19
12.3 KEY PLAYERS
12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
12.4.1 MONOCLONAL ANTIBODIES
12.4.2 INTERFERON
12.4.3 ERYTHROPOIETIN
12.4.4 INSULIN
12.4.5 VACCINES
12.4.6 OTHERS
12.4.7
12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
12.5.1 TUMOR
12.5.2 DIABETES
12.5.3 CARDIOVASCULAR
12.5.4 HEMOPHILIA
12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
12.6.1 TURKEY
12.6.2 SAUDI ARABIA
12.6.3 IRAN
12.6.4 UAE
12.6.5 AFRICA
12.6.6 REST OF MEA
CHAPTER 13: SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.2 IMPACT OF COVID-19
13.3 KEY PLAYERS
13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
13.4.1 MONOCLONAL ANTIBODIES
13.4.2 INTERFERON
13.4.3 ERYTHROPOIETIN
13.4.4 INSULIN
13.4.5 VACCINES
13.4.6 OTHERS
13.4.7
13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
13.5.1 TUMOR
13.5.2 DIABETES
13.5.3 CARDIOVASCULAR
13.5.4 HEMOPHILIA
13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
13.6.1 BRAZIL
13.6.2 ARGENTINA
13.6.3 REST OF SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BIOLOGICS AND BIOSIMILARS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BIOLOGICS AND BIOSIMILARS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BIOLOGICS AND BIOSIMILARS MARKET COMPETITIVE RIVALRY
TABLE 005. BIOLOGICS AND BIOSIMILARS MARKET THREAT OF NEW ENTRANTS
TABLE 006. BIOLOGICS AND BIOSIMILARS MARKET THREAT OF SUBSTITUTES
TABLE 007. BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
TABLE 008. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
TABLE 009. INTERFERON MARKET OVERVIEW (2016-2028)
TABLE 010. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
TABLE 011. INSULIN MARKET OVERVIEW (2016-2028)
TABLE 012. VACCINES MARKET OVERVIEW (2016-2028)
TABLE 013. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 014. MARKET OVERVIEW (2016-2028)
TABLE 015. BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
TABLE 016. TUMOR MARKET OVERVIEW (2016-2028)
TABLE 017. DIABETES MARKET OVERVIEW (2016-2028)
TABLE 018. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
TABLE 019. HEMOPHILIA MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 021. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 022. N BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 023. EUROPE BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 024. EUROPE BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 025. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 026. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 027. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 028. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 029. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 030. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 031. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 032. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 033. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 034. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 035. ROCHE: SNAPSHOT
TABLE 036. ROCHE: BUSINESS PERFORMANCE
TABLE 037. ROCHE: PRODUCT PORTFOLIO
TABLE 038. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. AMGEN: SNAPSHOT
TABLE 039. AMGEN: BUSINESS PERFORMANCE
TABLE 040. AMGEN: PRODUCT PORTFOLIO
TABLE 041. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. ABBVIE: SNAPSHOT
TABLE 042. ABBVIE: BUSINESS PERFORMANCE
TABLE 043. ABBVIE: PRODUCT PORTFOLIO
TABLE 044. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. SANOFI-AVENTIS: SNAPSHOT
TABLE 045. SANOFI-AVENTIS: BUSINESS PERFORMANCE
TABLE 046. SANOFI-AVENTIS: PRODUCT PORTFOLIO
TABLE 047. SANOFI-AVENTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. JOHNSON & JOHNSON: SNAPSHOT
TABLE 048. JOHNSON & JOHNSON: BUSINESS PERFORMANCE
TABLE 049. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 050. JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. PFIZER: SNAPSHOT
TABLE 051. PFIZER: BUSINESS PERFORMANCE
TABLE 052. PFIZER: PRODUCT PORTFOLIO
TABLE 053. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. NOVO NORDISK: SNAPSHOT
TABLE 054. NOVO NORDISK: BUSINESS PERFORMANCE
TABLE 055. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 056. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. ELI LILLY: SNAPSHOT
TABLE 057. ELI LILLY: BUSINESS PERFORMANCE
TABLE 058. ELI LILLY: PRODUCT PORTFOLIO
TABLE 059. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. NOVARTIS: SNAPSHOT
TABLE 060. NOVARTIS: BUSINESS PERFORMANCE
TABLE 061. NOVARTIS: PRODUCT PORTFOLIO
TABLE 062. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. MERCK: SNAPSHOT
TABLE 063. MERCK: BUSINESS PERFORMANCE
TABLE 064. MERCK: PRODUCT PORTFOLIO
TABLE 065. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. 3SBIO: SNAPSHOT
TABLE 066. 3SBIO: BUSINESS PERFORMANCE
TABLE 067. 3SBIO: PRODUCT PORTFOLIO
TABLE 068. 3SBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. CHANGCHUN HIGH TECH: SNAPSHOT
TABLE 069. CHANGCHUN HIGH TECH: BUSINESS PERFORMANCE
TABLE 070. CHANGCHUN HIGH TECH: PRODUCT PORTFOLIO
TABLE 071. CHANGCHUN HIGH TECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. CP GUOJIAN: SNAPSHOT
TABLE 072. CP GUOJIAN: BUSINESS PERFORMANCE
TABLE 073. CP GUOJIAN: PRODUCT PORTFOLIO
TABLE 074. CP GUOJIAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. BIOTECH: SNAPSHOT
TABLE 075. BIOTECH: BUSINESS PERFORMANCE
TABLE 076. BIOTECH: PRODUCT PORTFOLIO
TABLE 077. BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. GELGEN: SNAPSHOT
TABLE 078. GELGEN: BUSINESS PERFORMANCE
TABLE 079. GELGEN: PRODUCT PORTFOLIO
TABLE 080. GELGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. INNOVENT: SNAPSHOT
TABLE 081. INNOVENT: BUSINESS PERFORMANCE
TABLE 082. INNOVENT: PRODUCT PORTFOLIO
TABLE 083. INNOVENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. DONG BAO: SNAPSHOT
TABLE 084. DONG BAO: BUSINESS PERFORMANCE
TABLE 085. DONG BAO: PRODUCT PORTFOLIO
TABLE 086. DONG BAO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. GANLEE: SNAPSHOT
TABLE 087. GANLEE: BUSINESS PERFORMANCE
TABLE 088. GANLEE: PRODUCT PORTFOLIO
TABLE 089. GANLEE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 089. UNITED LABORATORIES: SNAPSHOT
TABLE 090. UNITED LABORATORIES: BUSINESS PERFORMANCE
TABLE 091. UNITED LABORATORIES: PRODUCT PORTFOLIO
TABLE 092. UNITED LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 092. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 093. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 094. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 095. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BIOLOGICS AND BIOSIMILARS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BIOLOGICS AND BIOSIMILARS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BIOLOGICS AND BIOSIMILARS MARKET COMPETITIVE RIVALRY
TABLE 005. BIOLOGICS AND BIOSIMILARS MARKET THREAT OF NEW ENTRANTS
TABLE 006. BIOLOGICS AND BIOSIMILARS MARKET THREAT OF SUBSTITUTES
TABLE 007. BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
TABLE 008. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
TABLE 009. INTERFERON MARKET OVERVIEW (2016-2028)
TABLE 010. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
TABLE 011. INSULIN MARKET OVERVIEW (2016-2028)
TABLE 012. VACCINES MARKET OVERVIEW (2016-2028)
TABLE 013. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 014. MARKET OVERVIEW (2016-2028)
TABLE 015. BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
TABLE 016. TUMOR MARKET OVERVIEW (2016-2028)
TABLE 017. DIABETES MARKET OVERVIEW (2016-2028)
TABLE 018. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
TABLE 019. HEMOPHILIA MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 021. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 022. N BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 023. EUROPE BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 024. EUROPE BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 025. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 026. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 027. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 028. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 029. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 030. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 031. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 032. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 033. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 034. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 035. ROCHE: SNAPSHOT
TABLE 036. ROCHE: BUSINESS PERFORMANCE
TABLE 037. ROCHE: PRODUCT PORTFOLIO
TABLE 038. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. AMGEN: SNAPSHOT
TABLE 039. AMGEN: BUSINESS PERFORMANCE
TABLE 040. AMGEN: PRODUCT PORTFOLIO
TABLE 041. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. ABBVIE: SNAPSHOT
TABLE 042. ABBVIE: BUSINESS PERFORMANCE
TABLE 043. ABBVIE: PRODUCT PORTFOLIO
TABLE 044. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. SANOFI-AVENTIS: SNAPSHOT
TABLE 045. SANOFI-AVENTIS: BUSINESS PERFORMANCE
TABLE 046. SANOFI-AVENTIS: PRODUCT PORTFOLIO
TABLE 047. SANOFI-AVENTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. JOHNSON & JOHNSON: SNAPSHOT
TABLE 048. JOHNSON & JOHNSON: BUSINESS PERFORMANCE
TABLE 049. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 050. JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. PFIZER: SNAPSHOT
TABLE 051. PFIZER: BUSINESS PERFORMANCE
TABLE 052. PFIZER: PRODUCT PORTFOLIO
TABLE 053. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. NOVO NORDISK: SNAPSHOT
TABLE 054. NOVO NORDISK: BUSINESS PERFORMANCE
TABLE 055. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 056. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. ELI LILLY: SNAPSHOT
TABLE 057. ELI LILLY: BUSINESS PERFORMANCE
TABLE 058. ELI LILLY: PRODUCT PORTFOLIO
TABLE 059. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. NOVARTIS: SNAPSHOT
TABLE 060. NOVARTIS: BUSINESS PERFORMANCE
TABLE 061. NOVARTIS: PRODUCT PORTFOLIO
TABLE 062. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. MERCK: SNAPSHOT
TABLE 063. MERCK: BUSINESS PERFORMANCE
TABLE 064. MERCK: PRODUCT PORTFOLIO
TABLE 065. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. 3SBIO: SNAPSHOT
TABLE 066. 3SBIO: BUSINESS PERFORMANCE
TABLE 067. 3SBIO: PRODUCT PORTFOLIO
TABLE 068. 3SBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. CHANGCHUN HIGH TECH: SNAPSHOT
TABLE 069. CHANGCHUN HIGH TECH: BUSINESS PERFORMANCE
TABLE 070. CHANGCHUN HIGH TECH: PRODUCT PORTFOLIO
TABLE 071. CHANGCHUN HIGH TECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. CP GUOJIAN: SNAPSHOT
TABLE 072. CP GUOJIAN: BUSINESS PERFORMANCE
TABLE 073. CP GUOJIAN: PRODUCT PORTFOLIO
TABLE 074. CP GUOJIAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. BIOTECH: SNAPSHOT
TABLE 075. BIOTECH: BUSINESS PERFORMANCE
TABLE 076. BIOTECH: PRODUCT PORTFOLIO
TABLE 077. BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. GELGEN: SNAPSHOT
TABLE 078. GELGEN: BUSINESS PERFORMANCE
TABLE 079. GELGEN: PRODUCT PORTFOLIO
TABLE 080. GELGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. INNOVENT: SNAPSHOT
TABLE 081. INNOVENT: BUSINESS PERFORMANCE
TABLE 082. INNOVENT: PRODUCT PORTFOLIO
TABLE 083. INNOVENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. DONG BAO: SNAPSHOT
TABLE 084. DONG BAO: BUSINESS PERFORMANCE
TABLE 085. DONG BAO: PRODUCT PORTFOLIO
TABLE 086. DONG BAO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. GANLEE: SNAPSHOT
TABLE 087. GANLEE: BUSINESS PERFORMANCE
TABLE 088. GANLEE: PRODUCT PORTFOLIO
TABLE 089. GANLEE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 089. UNITED LABORATORIES: SNAPSHOT
TABLE 090. UNITED LABORATORIES: BUSINESS PERFORMANCE
TABLE 091. UNITED LABORATORIES: PRODUCT PORTFOLIO
TABLE 092. UNITED LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 092. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 093. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 094. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 095. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY TYPE
FIGURE 012. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
FIGURE 013. INTERFERON MARKET OVERVIEW (2016-2028)
FIGURE 014. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
FIGURE 015. INSULIN MARKET OVERVIEW (2016-2028)
FIGURE 016. VACCINES MARKET OVERVIEW (2016-2028)
FIGURE 017. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 018. MARKET OVERVIEW (2016-2028)
FIGURE 019. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY APPLICATION
FIGURE 020. TUMOR MARKET OVERVIEW (2016-2028)
FIGURE 021. DIABETES MARKET OVERVIEW (2016-2028)
FIGURE 022. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
FIGURE 023. HEMOPHILIA MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY TYPE
FIGURE 012. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
FIGURE 013. INTERFERON MARKET OVERVIEW (2016-2028)
FIGURE 014. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
FIGURE 015. INSULIN MARKET OVERVIEW (2016-2028)
FIGURE 016. VACCINES MARKET OVERVIEW (2016-2028)
FIGURE 017. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 018. MARKET OVERVIEW (2016-2028)
FIGURE 019. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY APPLICATION
FIGURE 020. TUMOR MARKET OVERVIEW (2016-2028)
FIGURE 021. DIABETES MARKET OVERVIEW (2016-2028)
FIGURE 022. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
FIGURE 023. HEMOPHILIA MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
